The Europe Smart Insulin Pens Market would witness market growth of 10.3% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 138.6 thousand units, showcasing a growth of 9.8% (2019-2022).
These pens represent a significant leap forward in diabetes management, offering a range of features that enhance the precision, convenience, and patient engagement associated with insulin therapy. These pens are equipped with advanced technologies, including Bluetooth connectivity, dose tracking, and dose calculation capabilities, that empower patients to better monitor and manage their insulin regimens. By enabling the automatic tracking of insulin doses, these devices simplify record-keeping and offer insightful data that healthcare professionals can analyse to tailor treatment plans to individual patient needs.
Advances in patient adherence, monitoring, and technique have resulted from the development of diabetes management technologies. Insulin pens, for instance, offer a number of benefits over syringes and vials, including better adherence, less pain at the injection site, and increased patient satisfaction. With the increasing number of people with diabetes, second-generation insulin pens have been designed with USB or Bluetooth capabilities for more precise medication monitoring. Likewise, numerous blood glucose self-monitoring gadgets have incorporated Bluetooth technology to facilitate wireless data transfer to smartphones.
Many European healthcare systems are adopting digital health technologies and integrating them into their infrastructure. These pens can be easily incorporated into electronic health records (EHR) and telemedicine platforms, making them an integral part of diabetes management in clinical settings. These policies create an enabling environment for the adoption of these devices. The usage of these pens in Europe is driven by technological advancements, data-driven healthcare, healthcare provider endorsements, supportive policies, personalized medicine, and the region's focus on patient engagement and well-being. As the adoption of these devices continues to grow, they are expected to play an increasingly significant role in improving diabetes management and patient outcomes in Europe.
The Germany market dominated the Europe Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $12,976 Thousands by 2030. The UK market is exhibiting a CAGR of 9.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 11.2% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
These pens represent a significant leap forward in diabetes management, offering a range of features that enhance the precision, convenience, and patient engagement associated with insulin therapy. These pens are equipped with advanced technologies, including Bluetooth connectivity, dose tracking, and dose calculation capabilities, that empower patients to better monitor and manage their insulin regimens. By enabling the automatic tracking of insulin doses, these devices simplify record-keeping and offer insightful data that healthcare professionals can analyse to tailor treatment plans to individual patient needs.
Advances in patient adherence, monitoring, and technique have resulted from the development of diabetes management technologies. Insulin pens, for instance, offer a number of benefits over syringes and vials, including better adherence, less pain at the injection site, and increased patient satisfaction. With the increasing number of people with diabetes, second-generation insulin pens have been designed with USB or Bluetooth capabilities for more precise medication monitoring. Likewise, numerous blood glucose self-monitoring gadgets have incorporated Bluetooth technology to facilitate wireless data transfer to smartphones.
Many European healthcare systems are adopting digital health technologies and integrating them into their infrastructure. These pens can be easily incorporated into electronic health records (EHR) and telemedicine platforms, making them an integral part of diabetes management in clinical settings. These policies create an enabling environment for the adoption of these devices. The usage of these pens in Europe is driven by technological advancements, data-driven healthcare, healthcare provider endorsements, supportive policies, personalized medicine, and the region's focus on patient engagement and well-being. As the adoption of these devices continues to grow, they are expected to play an increasingly significant role in improving diabetes management and patient outcomes in Europe.
The Germany market dominated the Europe Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $12,976 Thousands by 2030. The UK market is exhibiting a CAGR of 9.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 11.2% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
Scope of the Study
Market Segments Covered in the Report:
By Usability (Volume, Thousand Units, Revenue, USD Million, 2019-30)- Prefilled
- Reusable
- First Generation Pens
- Second Generation Pens
- USB Connected
- Bluetooth-Enabled
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Smart Insulin Pens Market, By Usability
Chapter 6. Europe Smart Insulin Pens Market, By Product
Chapter 7. Europe Smart Insulin Pens Market, By End User
Chapter 8. Europe Smart Insulin Pens Market, By Country
Chapter 9. Company Profiles
Companies Mentioned
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F. Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Methodology
LOADING...
